World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

GenomOncology Announces Strategic Partnership with WeTrials to Accelerate Clinical Trial Enrollment for CNS Cancer Patients

Cision PR Newswire by Cision PR Newswire
March 10, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

CLEVELAND, March 10, 2026 /PRNewswire/ — GenomOncology, a leading precision medicine software company, today announced a strategic partnership with WeTrials, an AI-powered patient engagement and trial enablement platform, to help CNS cancer patients access and enroll in clinical trials faster. In addition to being made available to all customers at GenomOncology. The collaboration also expands on the existing partnership between GenomOncology and Belay Diagnostics, creating a more complete pathway from molecular diagnosis to trial enrollment.


New GO Logo (PRNewsfoto/GenomOncology)

Earlier this year, Belay Diagnostics integrated GenomOncology’s GO Pathology Workbench into its variant interpretation workflow for its Summit™ 2.0 liquid biopsy test — a cerebrospinal fluid (CSF) assay that informs the diagnosis and management of primary and secondary central nervous system (CNS) malignancies. Building on that foundation, the GO Genomic Report generated through this workflow will now include a direct link to the WeTrials platform. With a single click, clinicians can move from a patient’s molecular report, including GenomOncology’s matched clinical trial recommendations, directly into WeTrials’ patient-friendly trial information page, where complex studies are simplified, and patients can easily explore enrollment options.

“We built WeTrials on the belief that clinical trials should never be the last resort, but a first consideration,” said Alireza Mansouri, MD, Co-Founder and CMO, WeTrials. “When a clinician, or even a patient, can go directly from a genomic report to our platform, then pursue trial enrollment in a streamlined process, the barriers to enrollment drop significantly. Together with GenomOncology and Belay Diagnostics, we can ensure that molecular insights open the door to innovative therapies patients might otherwise never have known existed.”

“Our goal has always been to make sure the molecular information uncovered through the Summit™ test translates into real options for patients,” said Dr. Honey Reddi, PhD, FACMG, Chief Laboratory Officer, Belay Diagnostics. “This collaboration with WeTrials puts the right resources directly in the hands of clinicians at the point of reporting, so, when advised, patients can move from diagnosis to clinical trial enrollment faster than ever before.”

“The trial matches we surface in our genomic reports need to lead to action,” said Garreth Hippe, Chief Commercial Officer, GenomOncology. “By embedding a direct link to WeTrials within the GO Genomic Report, we’re giving clinicians an immediate on-ramp to enrollment support without adding complexity to their workflow. We’re proud to expand on the outstanding work with Belay Diagnostics to build something that truly puts patients first, and not just for Belay but for all of our customers.”

The initial phase of the partnership will focus on CNS cancer patients tested through Belay Diagnostics, with plans to expand to additional diagnostic partners and cancer types over time.

About GenomOncology 

GenomOncology transforms complex clinical and molecular data into actionable intelligence for precision cancer care. The company’s reporting solutions deliver embedded decision support for clinical genomic reporting and clinical trial optimization that seamlessly integrates into clinical workflows to better enable accurate decision-making for patient treatment. Visit www.genomoncology.com.

About WeTrials 

WeTrials is an AI-powered patient engagement platform that helps patients and clinicians discover, understand, and pursue relevant clinical trials. By translating complex trial information into clear, patient-friendly guidance and connecting patients with study sites, WeTrials helps accelerate trial awareness, access, and enrollment. Learn more at www.wetrials.com.

About Belay Diagnostics

At Belay Diagnostics, our mission is to serve patients and those who care for them. Belay’s Summit™, Ascent™ and Vantage™ liquid biopsy tests in CSF inform diagnosis, therapeutic actionability, and clinical trial options for those with CNS tumors and malignancies. Learn more at www.belaydiagnostics.com.

Media Contact

Gretchen Kemp
GenomOncology
pr@genomoncology.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/genomoncology-announces-strategic-partnership-with-wetrials-to-accelerate-clinical-trial-enrollment-for-cns-cancer-patients-302709691.html

SOURCE GenomOncology

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • Forge Insurance Becomes First Carrier to Launch ePayPolicy and Majesco Integration, Unlocking Massive Savings and Financial Automation

    0 shares
    Share 0 Tweet 0
  • Armor Health Delivers Promising Results in First Three Months at Blair County Prison, Pennsylvania

    0 shares
    Share 0 Tweet 0
  • Rock Gate Partners Announces Acquisition of Blast Deflectors, Inc.

    0 shares
    Share 0 Tweet 0
  • MySize Reports Third Quarter and Nine-Month 2026 Financial Results; Nine-Month Revenue Up 21%, Advances Operational Restructuring and Strategic Diversification

    0 shares
    Share 0 Tweet 0
  • Lincoln CEO Rob Brown to Speak at the 2026 Goldman Sachs Financial Services Conference

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler